COVID

Question 1

Nirmatrelvir- Ritonavir

MOA:
AE:
Efficacy:

Answer 1

MOA: inhibits viral protease enzyme (Mpro) = prevent viral replication

AE:

• Dose must be decreased for patients w/ renal dysfunction
• CYP 3A4 inhibitors = potential for serous drug interactions

-Efficacy: High

Question 2

Remdesivir

MOA:
AE:
Efficacy

Answer 2

MOA: Inhibits viral RNA polymerase = disrupt viral replication
(active metabolite incorporated into viral RNA)

AE: IV for 3 days

Efficacy: Strong

First FDA approved Covid drug

Prodrug, converted into ATP analog inside cells (nucleotide analog)

Question 3

Molnupiravir

MOA:
AE:
Efficacy:

Answer 3

MOA: Competes w/ cytidine triphosphate for incorporation into viral RNA –> creates extensive mutations in viral RNA

AE: Bone/ cartilage toxicity = not recommended for : children under 18, Pregnant ppl/ Anyone of childbearing potential

Efficacy: Not significant

Prodrug: nucleoside analog

Question 4

Sotromivab

MOA:
AE:
Efficacy:

Answer 4

Monoclonal Antibody

MOA: mAb binding to virus blocks fusion & prevents viral entry into host cell (binds spike proteins)

AE: low availability, IV

Efficacy: High, effective against omicron, preferred option for symptomatic outpatients w/ severe risk of disease